293/CHE-Fc細(xì)胞

數(shù)量： 大量

年限： *****

細(xì)胞形態(tài)： 上皮樣

ATCC Number： CRL-2730?

相關(guān)**： 腺癌

器官來(lái)源： 前列腺

細(xì)胞類型： 上皮細(xì)胞

生長(zhǎng)狀態(tài)： 貼壁生長(zhǎng)

運(yùn)輸方式： 凍存運(yùn)輸

是否是腫瘤細(xì)胞： 0

物種來(lái)源： 轉(zhuǎn)基因小鼠

293/CHE-Fc細(xì)胞品系： C57BL/6-TgN(TRAMP)8247Ng

Designations: TRAMP-C1

Depositors: N Greenberg

Biosafety Level: 2 [Cells contain SV40 DNA viral sequences ]

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Mus musculus, transgenic deposited as mouse, transgenic

Morphology: epithelial

Source: Organ: prostate

Strain: C57BL/6-TgN(TRAMP)8247Ng

Disease: 293/CHE-Fc細(xì)胞adenocarcinoma

Cell Type: epithelial

Cellular Products: E-cadherin

cytokeratin

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. N. Greenberg and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as a service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Prior to purchase, for-profit commercial institutions must obtain a research use license. For instructions on how to proceed, please contact ATCC 's Office of Licensing, Contracts and Compliance via email at licensing@ATCC .org.

293/CHE-Fc細(xì)胞Isolation: Isolation date: 1996

Receptors: androgen receptor, expressed

Tumorigenic: Yes

Age: *****

Gender: male

Comments: The TRAMP-C1 (ATCC - CRL-2730), TRAMP- C2 (ATCC -CRL-2731) and TRAMP-C3 (ATCC CRL-2732) cell lines were derived in 1996 from a heterogeneous 32 week primary tumor in the prostate of a PB-Tag C57BL/6 (TRAMP) mouse. TRAMP is a transgenic line of C57BL/6 mice harboring a construct comprised of the minimal -426/+28 rat probasin promoter (426 base pairs of the rat probasin (PB) gene promoter and 28 base pairs of 5'-untranslated region) to target expression of the SV40 large T antigen to prostatic epithelium. Neither the cells grown in culture, nor the tumors arising from the cells in vivo, express SV40 T antigen (Tag). TRAMP-C1 and TRAMP-C2 are tumorigenic when grafted into syngeneic C57BL/6 hosts. However, TRAMP-C3 grows readily in vitro, but does not form tumors. These cell lines represent various stages of cellular transformation and progression to androgen-independent metastatic disease that can be manipulated in vitro. The cell lines can be used in studies to elucidate molecular mechanisms associated with the initiation, progression and metastasis of prostate cancer. They are also a useful tool for gene/drug discovery.

Propagation: ATCC complete growth medium: Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose supplemented with 0.005 mg/ml bovine insulin and 10 nM dehydroisoandrosterone, 90%; fetal bovine serum, 5%; Nu-Serum IV, 5%.

Atmosphere: air, 95%; carbon dioxide (CO2), 5%

Temperature: 37.0°C

Subculturing: 293/CHE-Fc細(xì)胞Protocol:

Remove and discard culture medium.

Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.

Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).

Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal.

Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.

Add appropriate aliquots of the cell suspension to new culture vessels.

Incubate cultures at 37?C.

Subcultivation Ratio: A subcultivation ratio of 1:6 to 1:10 is recommended

Medium Renewal: Two to three times weekly

Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO

Storage temperature: liquid nitrogen vapor phase

Doubling Time: 25 hrs

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002

recommended serum:ATCC 30-2020

References: 29102: Hurwitz AA, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA 94: 8099-8103, 1997. PubMed: 9223321

57821: Foster BA, et al. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 57: 3325-3330, 1997. 293/CHE-Fc細(xì)胞PubMed: 9269988

61281: Greenberg NM, et al. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 92: 3439-3443, 1995. PubMed: 7724580

61282: Greenberg NM, et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol. Endocrinol. 8: 230-239, 1994. PubMed: 8170479

61283: Gingrich JR, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 56: 4096-4102, 1996. PubMed: 8797572

61284: Greenberg NM. Transgenic models for prostate cancer research. Urol. Oncol. 2: 119-122, 1996.

61285: Gingrich JR, et al. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res. 57: 4687-4691, 1997. PubMed: 9354422